progesterone Side Effects
Also known as: Prometrium
Analysis of 21,004 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
21,004
Death-Related
476
2.3% of reports
Hospitalizations
3,394
16.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 476 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| OFF LABEL USE | 134 |
| FOETAL DEATH | 129 |
| THROMBOCYTOPENIA | 129 |
| PYREXIA | 126 |
| HEADACHE | 125 |
| PAIN | 125 |
| PSORIASIS | 121 |
| DRUG INEFFECTIVE | 120 |
| DRUG INTOLERANCE | 120 |
| FATIGUE | 120 |
| HYPERTENSION | 120 |
| PRESCRIBED OVERDOSE | 118 |
| RHEUMATOID ARTHRITIS | 118 |
| TEMPERATURE REGULATION DISORDER | 118 |
| UPPER RESPIRATORY TRACT INFECTION | 118 |
| FLUID RETENTION | 117 |
| HEPATIC ENZYME INCREASED | 116 |
| JOINT SWELLING | 116 |
| PRODUCT USE ISSUE | 116 |
| CONTRAINDICATED PRODUCT ADMINISTERED | 115 |
Reactions in Hospitalization Reports
Top reactions in 3,394 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| OVARIAN HYPERSTIMULATION SYNDROME | 266 |
| DYSPNOEA | 250 |
| FATIGUE | 241 |
| HEADACHE | 236 |
| NAUSEA | 234 |
| OFF LABEL USE | 207 |
| PAIN | 205 |
| VOMITING | 186 |
| DIARRHOEA | 173 |
| DIZZINESS | 166 |
| PYREXIA | 162 |
| MATERNAL EXPOSURE DURING PREGNANCY | 156 |
| FALL | 146 |
| DRUG INEFFECTIVE | 141 |
| ABDOMINAL PAIN | 136 |
| ANXIETY | 135 |
| ARTHRALGIA | 132 |
| ASTHENIA | 128 |
| PNEUMONIA | 120 |
| FOETAL EXPOSURE DURING PREGNANCY | 117 |
Nearby — Related Medications
What the FAERS Data Reveals About progesterone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 21,004 voluntary reports linked to progesterone and its brand equivalents (Prometrium), spanning 2004 through 2025. Of those, 476 (2.3%) listed death as an outcome and 3,394 (16.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 97% were female and 3% male; age distribution skews toward 45-64, with 6,819 reports in that bracket. The single most reported reaction is headache with 1,946 submissions, followed by off label use and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.